The expression landscape and heterogeneity of nectin-4, HER2, and Trop-2 in urothelial carcinoma: clinicopathological correlations and implications for ADC-guided precision therapy - Takeaways - MDSpire

The expression landscape and heterogeneity of nectin-4, HER2, and Trop-2 in urothelial carcinoma: clinicopathological correlations and implications for ADC-guided precision therapy

  • By

  • Shaobo Qin

  • Zhicheng Dai

  • Zhenxing Hu

  • Xiaohui Wang

  • Huiyan Zhang

  • Haotian Yang

  • Jie Liu

  • Lianghong Ma

  • July 8, 2026

  • 0 min

Share

  • 1

    The study analyzed 118 urothelial carcinoma specimens to map expression patterns of Nectin-4, HER2, and Trop-2 for personalized ADC therapy.

  • 2

    High expression of at least one target was found in 90.7% of patients, with 56.8% exhibiting multi-target co-expression.

  • 3

    HER2 and Trop-2 showed significant upregulation from carcinoma in situ to invasive carcinoma, indicating potential progression markers.

  • 4

    Nectin-4 expression tended to downregulate in metastases, while Trop-2 was significantly higher in the lower urinary tract.

  • 5

    The study introduced a novel Δscore metric to quantify antigenic gain and predict aggressive phenotypes in urothelial carcinoma.

Original Source(s)

The expression landscape and heterogeneity of nectin-4, HER2, and Trop-2 in urothelial carcinoma: clinicopathological correlations and implications for ADC-guided precision therapy

  • by Shaobo Qin, Zhicheng Dai, Zhenxing Hu, Xiaohui Wang, Huiyan Zhang, Haotian Yang, Jie Liu, Lianghong Ma

  • July 8, 2026

Related Content

Effects of different art therapies on the psychological well-being and quality of life in cancer survivors: a systematic review and network meta-analysis

The role of 18F-FDG PET/CT in identifying risk factors for ground-glass nodules in invasive lung adenocarcinoma

Unraveling the role of PPFIA1 in cancer: a comprehensive multi-omics analysis and functional validation from pan-cancer to pancreatic cancer